Centre for Haemato-Oncology

Welcome to the Centre for Haemato-Oncology, where our main mission is to find cures for haematologic malignancies. We are a centre of excellence in state-of-the-art research and clinical translation, which brings together internationally-recognised basic scientists with top clinical  academics. Our central aim is to understand the biology of leukaemias and lymphomas and harness this knowledge to identify new treatment strategies. Working closely together with the Haemato-oncology department at the St Bartholomew’s Hospital Cancer Centre we are uniquely well placed to implement our findings in clinical practice. Moreover, our Centre is embedded in Barts and The London School of Medicine and Dentistry, one of the UK’s top medical schools, thus offering excellent opportunities for multidisciplinary collaborations.

Our main research themes and their associated faculty include:

  1. Stem cell biology and normal haematopoiesis (Laboratories: Ficz, Ganuza, Kranc, Rouault-Pierre)
  2. Biology and therapeutic targeting of leukaemia (Laboratories: Gribben, Gallipoli, Kranc, Krysov, Riches, Rouault-Pierre, Wrench, Cutillas)
  3. Pathogenesis and treatment of lymphomas (Laboratories: Braun, Okosun, Riches, Fitzgibbon)
  4. Improving immunotherapy in blood malignancies (Laboratories: Davies, Gribben, Le Dieu)

Contact us

Centre Lead: Professor John Gribben

Deputy Centre Lead: Professor Kamil Kranc

Lab Manager: Dr Rebecca Gresham

Centre Administrator: Elen McCabe

3rd Floor, John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ

Recent Publications

  • Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia. Cell Stem Cell (2019) S1934-5909(19)30120-1. PMID: 31031138
  • Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood (2019) 133(2) 2765-2775. PMID: 30862645
  • Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Mol Oncol (2019) 13(2) 1075-1091. PMID: 30690892
  • AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol (2019) 37(14):1188-1199. PMID: 30897038

Latest News

  • Researchers from the Centre attended the American Society of Hematology (ASH) Annual Meeting and Exposition, which this year took place in Orlando, Florida on 7th-10th December. Oral presentations were given by Dr Jessica Okosun, Dr Joseph Taylor, Dr James Aries and Dr Robin Sanderson. Poster presentations were given by Dr Findlay Copley, Dr Emily Saunderson and Arantxa Romero-Toledo. Find out more here.
  • Bloodwise supporters recently visited the Centre as part of the Bloodwise Laboratory Tour programme. Find out more about the day here.
  • Dr Hannah Lawson from the Kranc Group won the Translational Medicine award during the William Harvey Day 2019.
  • Congratulations to Prof John Gribben who has been announced as the new President for the European Hematology Association.
  • Eliminating cancer stem cells: Scientists discover a novel drug target for aggressive blood cancer. New publication by Prof Kranc and team.
  • Dr Jessica Okosun spoke to CRUK about her role as a clinician scientist. Read the interview here.
  • Dr John Riches swapped his lab coat for legislation when he visited the House of Commons as part of the Royal Society's Pairing Scheme.

Areas of focus

Acute myeloid leukaemia
DLBCL - CD20 IHC
Lymphoma
FL cropped
Acute lymphoblastic leukaemia
DLBCL immunofluorescence - PMCH FITC
Chronic lymphocytic leukaemia
Follicular lymphoma - H&E
Stem Cell Biology
Hodgkins - EBV in situ hydribisation - blue
Immunotherapy
Vessels (CD31) CLL/SLL
Upcoming Events
  1. MSc Surgical Programmes Online Open Event

    June 2 @ 2:00 pm - 4:00 pm
  2. The London Pancreas Workshop 2020

    September 11 @ 9:30 am - 4:30 pm
© 2013 ~ 2020 Cancer Research UK Barts Centre